Alvotech’s Latest FDA Knockback Cuts It Fine For Humira Rival
AVT02 Adalimumab Biosimilar Receives A Further CRL From US Regulator After Inspection
Alvotech has received a further complete response letter from the US FDA relating to its AVT02 proposed adalimumab biosimilar rival to Humira. The latest BsUFA goal date disclosed for the product is now just a few days ahead of a potential US launch.
